Carlinville Area Hospital | |
20733 N Broad Street, Carlinville, Illinois 62626 | |
(217) 854-3141 | |
Not Available |
Name | Carlinville Area Hospital |
---|---|
Type | Critical Access Hospital |
Location | 20733 N Broad Street, Carlinville, Illinois |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 141347 |
NPI Number | 1053425124 |
Organization Name | CARLINVILLE AREA HOSPITAL ASSOCIATION |
Doing Business As | CARLINVILLE AREA HOSPITAL |
Address | 20733 North Broad Street, Carlinville, IL 62626 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 217-854-3857 |
News Archive
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.
Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.
A comprehensive Australian study examining the global impact of suicide prevention approaches in young people has found that youth-specific interventions conducted in clinical, educational and community settings can be effective in reducing suicide-related behavior in young people at risk.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 9 days ago
NPI Number | 1548484710 |
Organization Name | CARLINVILLE AREA HOSPITAL ASSOCIATION |
Address | 20733 N Broad St, Carlinville, IL 62626 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 217-854-3141 |
News Archive
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.
Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.
A comprehensive Australian study examining the global impact of suicide prevention approaches in young people has found that youth-specific interventions conducted in clinical, educational and community settings can be effective in reducing suicide-related behavior in young people at risk.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 9 days ago
NPI Number | 1750457461 |
Organization Name | CARLINVILLE AREA HOSPITAL ASSOCIATION |
Doing Business As | CARLINVILLE AREA HOSPITAL |
Address | 20733 N Broad St, Carlinville, IL 62626 |
Hospital Type | General Acute Care Hospital |
Phone Number | 217-854-3141 |
News Archive
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.
Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.
A comprehensive Australian study examining the global impact of suicide prevention approaches in young people has found that youth-specific interventions conducted in clinical, educational and community settings can be effective in reducing suicide-related behavior in young people at risk.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 9 days ago
NPI Number | 1841366556 |
Organization Name | CARLINVILLE AREA HOSPITAL ASSOCIATION |
Doing Business As | CARLINVILLE AREA HOSPITAL |
Address | 20733 N Broad St, Carlinville, IL 62626 |
Hospital Type | General Acute Care Hospital |
Phone Number | 217-854-3141 |
News Archive
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.
Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.
A comprehensive Australian study examining the global impact of suicide prevention approaches in young people has found that youth-specific interventions conducted in clinical, educational and community settings can be effective in reducing suicide-related behavior in young people at risk.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 9 days ago
NPI Number | 1932275641 |
Organization Name | CARLINVILLE AREA HOSPITAL ASSOCIATION |
Doing Business As | CARLINVILLE AREA HOSPITAL |
Address | 20733 N Broad St, Carlinville, IL 62626 |
Hospital Type | General Acute Care Hospital - Critical Access |
Phone Number | 217-854-3141 |
News Archive
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.
Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.
A comprehensive Australian study examining the global impact of suicide prevention approaches in young people has found that youth-specific interventions conducted in clinical, educational and community settings can be effective in reducing suicide-related behavior in young people at risk.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 9 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published by Cell Press online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.
Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.
A comprehensive Australian study examining the global impact of suicide prevention approaches in young people has found that youth-specific interventions conducted in clinical, educational and community settings can be effective in reducing suicide-related behavior in young people at risk.
Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company's MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).
Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone's proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
› Verified 9 days ago
Carlinville Area Hospital Critical Access Hospital Location: 20733 N Broad Street, Carlinville, Illinois 62626 Phone: (217) 854-3141 |